In Vivo FRET Imaging to Predict the Risk Associated with Hepatic Accumulation of Squalene-Based Prodrug Nanoparticles.
Fiche publication
Date publication
février 2018
Journal
Advanced healthcare materials
Auteurs
Membres identifiés du Cancéropôle Est :
Dr KLYMCHENKO Andrey
Tous les auteurs :
Cayre F, Mura S, Andreiuk B, Sobot D, Gouazou S, Desmaële D, Klymchenko AS, Couvreur P
Lien Pubmed
Résumé
Förster resonance energy transfer (FRET) is used here for the first time to monitor the in vivo fate of nanoparticles made of the squalene-gemcitabine prodrug and two novel derivatives of squalene with the cyanine dyes 5.5 and 7.5, which behave as efficient FRET pair in the NIR region. Following intravenous administration, nanoparticles initially accumulate in the liver, then they show loss of their integrity within 2 h and clearance of the squalene bioconjugates is observed within 24 h. Such awareness is a key prerequisite before introduction into clinical settings.
Mots clés
FRET, in vivo noninvasive imaging, prodrug nanoparticles
Référence
Adv Healthc Mater. 2018 02;7(3):